Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Neuroprotective Drugs Market by Type (Cholinesterase inhibitors, Anti-inflammatory, Others), By Application (Alzheimer’s disease, Parkinson’s disease, Others) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Neuroprotective Drugs Market by Type (Cholinesterase inhibitors, Anti-inflammatory, Others), By Application (Alzheimer’s disease, Parkinson’s disease, Others) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 131703 3300 Pharma & Healthcare 377 245 Pages 4.7 (50)

Market Overview:

The global neuroprotective drugs market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of neurodegenerative diseases, rising geriatric population, and growing awareness about neuroprotective drugs. Based on type, the global neuroprotective drugs market is segmented into cholinesterase inhibitors, anti-inflammatory agents, and others. Cholinesterase inhibitors are expected to account for the largest share of the global neuroprotective drugs market in 2018 owing to their high efficacy in treating Alzheimer’s disease and other neurological disorders. Anti-inflammatory agents are also expected to witness significant growth during the forecast period due to their ability to reduce inflammation and protect neurons from damage. Based on application, the global Neuroprotective Drugs Market is segmented into Alzheimer’s disease, Parkinson’s disease, traumatic brain injury (TBI), stroke, and others (Huntington’s disease).

Global Neuroprotective Drugs Industry Outlook

Product Definition:

Neuroprotective drugs are drugs that protect neurons from damage or death. They are important for treating neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Huntington's disease.

Cholinesterase inhibitors:

Cholinesterase inhibitors are the drugs that inhibit the action of cholinesterase. Cholinesterase is an enzyme responsible for breaking down a chemical called acetylcholine which is important in helping nerve cells to communicate with each other. The most commonly used cholinesterase inhibitors are Donepezil, Exelon, and Neurontin.


An anti-inflammatory drug is any pharmaceutical agent that reduces the inflammatory response. The most common symptoms of inflammation are redness, heat, swelling, and pain. Inflammation can be caused by a wide variety of factors such as infections (bacterial or viral), autoimmune diseases (such as rheumatoid arthritis), food additives, and smoking among others.

Application Insights:

The others segment held the largest market share in 2017. This is due to the rising prevalence of neurodegenerative disorders, such as multiple sclerosis, brain cancer and spinal cord injuries. According to a study published by the National Center for Biotechnology Information (NCBI) in 2014, around 60% of all people suffering from neurological disorders are diagnosed after death. Therefore, increasing number of deaths caused by neurological disorders is boosting this segment growth.

Alzheimer¢â‚¬â„¢s disease application was one of the leading segments owing to high prevalence rate and government initiatives encouraging effective treatment for Alzheimer¢â‚¬â„¢s disease globally. For instance, in November 2016 Germany announced a ¢â€š¹100000$ research grant program for promising candidates developing drugs against Alzheimer's disease dementia). Such initiatives are expected to boost regional market growth over next few years.

Regional Analysis:

North America dominated the global market in 2017 owing to the presence of a large number of pharmaceutical companies and increased R&D expenditure. The region is expected to maintain its dominance over the forecast period due to increasing cases of neurodegenerative diseases, growing geriatric population, and rising healthcare expenditure.

Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to increasing awareness about potential treatment options for neurodegenerative diseases coupled with government support for medical research & development activities in emerging economies such as India & China. Moreover, an increase in disposable income levels will also boost market growth during this period.

Growth Factors:

  • Increasing incidence of neurological disorders: The global prevalence of neurological disorders is increasing at an alarming rate. This is primarily due to the aging population and the increased incidence of chronic diseases such as Alzheimer’s disease, Parkinson’s disease, and stroke. As a result, there is a growing demand for neuroprotective drugs that can help in the treatment or prevention of these conditions.
  • Advances in drug discovery and development: The field of neuroprotection has seen significant advances in recent years with the advent of new technologies and approaches for drug discovery and development. This has led to the emergence of novel neuroprotective drugs that are more effective and safer than traditional therapies.
  • Growing awareness about neurological disorders: There is a growing awareness among people about various neurological disorders such as Alzheimer’s disease, Parkinson’s disease, stroke, etc., Their symptoms, risk factors, and available treatments options. This has led to an increase in demand for neuroprotective drugs worldwide.

Scope Of The Report

Report Attributes

Report Details

Report Title

Neuroprotective Drugs Market Research Report

By Type

Cholinesterase inhibitors, Anti-inflammatory, Others

By Application

Alzheimer's disease, Parkinson's disease, Others

By Companies

Genervon Biopharmaceuticals (Canada), NeuroVive Pharmaceutical (Sweden), Ceregene (USA), BHRPharma (Thailand), Neuren Pharmaceuticals (Australia), Allon therapeutics (Canada), Bionure Inc. (USA)

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year


Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year


Number of Pages


Number of Tables & Figures


Customization Available

Yes, the report can be customized as per your need.

Global Neuroprotective Drugs Market Report Segments:

The global Neuroprotective Drugs market is segmented on the basis of:


Cholinesterase inhibitors, Anti-inflammatory, Others

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.


Alzheimer's disease, Parkinson's disease, Others

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Genervon Biopharmaceuticals (Canada)
  2. NeuroVive Pharmaceutical (Sweden)
  3. Ceregene (USA)
  4. BHRPharma (Thailand)
  5. Neuren Pharmaceuticals (Australia)
  6. Allon therapeutics (Canada)
  7. Bionure Inc. (USA)

Global Neuroprotective Drugs Market Overview

Highlights of The Neuroprotective Drugs Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. Cholinesterase inhibitors
    2. Anti-inflammatory
    3. Others
  1. By Application:

    1. Alzheimer's disease
    2. Parkinson's disease
    3. Others
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Neuroprotective Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Neuroprotective Drugs Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?

Neuroprotective drugs are medications that protect the brain from damage.

Some of the major players in the neuroprotective drugs market are Genervon Biopharmaceuticals (Canada), NeuroVive Pharmaceutical (Sweden), Ceregene (USA), BHRPharma (Thailand), Neuren Pharmaceuticals (Australia), Allon therapeutics (Canada), Bionure Inc. (USA).

The neuroprotective drugs market is expected to grow at a compound annual growth rate of 7.5%.

1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Neuroprotective Drugs Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Neuroprotective Drugs Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Neuroprotective Drugs Market - Supply Chain
   4.5. Global Neuroprotective Drugs Market Forecast
      4.5.1. Neuroprotective Drugs Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Neuroprotective Drugs Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. Neuroprotective Drugs Market Absolute $ Opportunity

5. Global Neuroprotective Drugs Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Neuroprotective Drugs Market Size and Volume Forecast by Type
      5.3.1. Cholinesterase inhibitors
      5.3.2. Anti-inflammatory
      5.3.3. Others
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Neuroprotective Drugs Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Neuroprotective Drugs Market Size and Volume Forecast by Application
      6.3.1. Alzheimer's disease
      6.3.2. Parkinson's disease
      6.3.3. Others
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Neuroprotective Drugs Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Neuroprotective Drugs Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Neuroprotective Drugs Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Neuroprotective Drugs Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Neuroprotective Drugs Demand Share Forecast, 2019-2029

9. North America Neuroprotective Drugs Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Neuroprotective Drugs Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Neuroprotective Drugs Market Size and Volume Forecast by Application
      9.4.1. Alzheimer's disease
      9.4.2. Parkinson's disease
      9.4.3. Others
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Neuroprotective Drugs Market Size and Volume Forecast by Type
      9.7.1. Cholinesterase inhibitors
      9.7.2. Anti-inflammatory
      9.7.3. Others
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Neuroprotective Drugs Demand Share Forecast, 2019-2029

10. Latin America Neuroprotective Drugs Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Neuroprotective Drugs Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Neuroprotective Drugs Market Size and Volume Forecast by Application
      10.4.1. Alzheimer's disease
      10.4.2. Parkinson's disease
      10.4.3. Others
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Neuroprotective Drugs Market Size and Volume Forecast by Type
      10.7.1. Cholinesterase inhibitors
      10.7.2. Anti-inflammatory
      10.7.3. Others
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Neuroprotective Drugs Demand Share Forecast, 2019-2029

11. Europe Neuroprotective Drugs Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Neuroprotective Drugs Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Neuroprotective Drugs Market Size and Volume Forecast by Application
      11.4.1. Alzheimer's disease
      11.4.2. Parkinson's disease
      11.4.3. Others
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Neuroprotective Drugs Market Size and Volume Forecast by Type
      11.7.1. Cholinesterase inhibitors
      11.7.2. Anti-inflammatory
      11.7.3. Others
   11.8. Basis Point Share (BPS) Analysis by Type
   11.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Neuroprotective Drugs Demand Share, 2019-2029

12. Asia Pacific Neuroprotective Drugs Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Neuroprotective Drugs Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Neuroprotective Drugs Market Size and Volume Forecast by Application
      12.4.1. Alzheimer's disease
      12.4.2. Parkinson's disease
      12.4.3. Others
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Neuroprotective Drugs Market Size and Volume Forecast by Type
      12.7.1. Cholinesterase inhibitors
      12.7.2. Anti-inflammatory
      12.7.3. Others
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Neuroprotective Drugs Demand Share, 2019-2029

13. Middle East & Africa Neuroprotective Drugs Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Neuroprotective Drugs Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Neuroprotective Drugs Market Size and Volume Forecast by Application
      13.4.1. Alzheimer's disease
      13.4.2. Parkinson's disease
      13.4.3. Others
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Neuroprotective Drugs Market Size and Volume Forecast by Type
      13.7.1. Cholinesterase inhibitors
      13.7.2. Anti-inflammatory
      13.7.3. Others
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Neuroprotective Drugs Demand Share, 2019-2029

14. Competition Landscape
   14.1. Global Neuroprotective Drugs Market: Market Share Analysis
   14.2. Neuroprotective Drugs Distributors and Customers
   14.3. Neuroprotective Drugs Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. Genervon Biopharmaceuticals (Canada) Overview Financials Developments Strategic Outlook
      14.4.2. NeuroVive Pharmaceutical (Sweden) Overview Financials Developments Strategic Outlook
      14.4.3. Ceregene (USA) Overview Financials Developments Strategic Outlook
      14.4.4. BHRPharma (Thailand) Overview Financials Developments Strategic Outlook
      14.4.5. Neuren Pharmaceuticals (Australia) Overview Financials Developments Strategic Outlook
      14.4.6. Allon therapeutics (Canada) Overview Financials Developments Strategic Outlook
      14.4.7. Bionure Inc. (USA) Overview Financials Developments Strategic Outlook
      14.4.8. COMPANY8 Overview Financials Developments Strategic Outlook
      14.4.9. COMPANY9 Overview Financials Developments Strategic Outlook
      14.4.10. COMPANY 10 Overview Financials Developments Strategic Outlook
      14.4.11. COMPANY 11 Overview Financials Developments Strategic Outlook
      14.4.12. COMPANY 12 Overview Financials Developments Strategic Outlook
      14.4.13. COMPANY 13 Overview Financials Developments Strategic Outlook
      14.4.14. COMPANY 14 Overview Financials Developments Strategic Outlook
      14.4.15. COMPANY 15 Overview Financials Developments Strategic Outlook
      14.4.16. COMPANY 16 Overview Financials Developments Strategic Outlook
      14.4.17. COMPANY 17 Overview Financials Developments Strategic Outlook
      14.4.18. COMPANY 18 Overview Financials Developments Strategic Outlook
      14.4.19. COMPANY 19 Overview Financials Developments Strategic Outlook
      14.4.20. COMPANY 20 Overview Financials Developments Strategic Outlook

Our Trusted Clients

Contact Us